Coronavirus (COVID-19) - Latest Information for Patients and Visitors

(La más reciente información para pacientes y visitantes)

 

Read Now (Lea ahora)
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19 (CRISIS)

view all Clinical Trials

Overview

This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg.

Contact

For more information about this trial or to inquire about eligibility, email breathe@tuhs.temple.edu or call 215-707-1359.